Verena Claudia Haage

This paper identifies APOE-ϵ4-induced fibronectin accumulation at the blood-brain barrier as a key mediator of astrocyte-endothelial dysfunction in Alzheimer's disease, highlighting it as a potential therapeutic target.

The paper identifies regulators of microglial activation states using CRISPR screens and single-cell transcriptomics, revealing functional roles of ZNF532, PRDM1, and DNMT1 in disease-associated microglial states.

This study shows that INPP5D/SHIP1 regulates endo-lysosomal function and cargo-selective phagocytosis in human microglia, linking its dysfunction to Alzheimer's disease pathology.

The paper uses automated image segmentation to identify CD74high microglia associated with cognitive decline in AD, linking transcriptomic and morphological features.

The paper introduces a proteomic tool to identify protein markers for human microglial states and validates their utility in purification and differentiation.

The paper uses single-cell data to identify factors regulating an Alzheimer's disease-related microglial signature and proposes a new analytic framework for microglial classification.

The paper uses HDAC inhibitors to mimic human DAM in vitro and identifies shared marker genes.

This paper introduces a cerebral organoid model with integrated microglia to study how inflammatory stimuli and microglial presence affect neurodevelopment and neurodevelopmental disorders.

The paper identifies Topoisomerase I inhibitors as immunomodulators for Alzheimer's disease by characterizing their effects on human microglial subtypes in vitro and in a zebrafish model.

This study identifies disease-enriched microglial subsets and validates compounds that modulate their states using single-cell RNA sequencing and in vitro experiments.